tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright
PremiumThe FlyKazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright
1M ago
Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium
Premium
Company Announcements
Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium
1M ago
Kazia Therapeutics announces presentation from paxalisib studies
Premium
The Fly
Kazia Therapeutics announces presentation from paxalisib studies
1M ago
Kazia Therapeutics announces pricing of $50M private placement
PremiumThe FlyKazia Therapeutics announces pricing of $50M private placement
1M ago
Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics
Premium
Ratings
Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics
2M ago
Closing Bell Movers: Plug Power slips after converible notes offering
Premium
The Fly
Closing Bell Movers: Plug Power slips after converible notes offering
2M ago
Buy Rating for Kazia Therapeutics Driven by Strategic Drug Approval and Licensing Initiatives
PremiumRatingsBuy Rating for Kazia Therapeutics Driven by Strategic Drug Approval and Licensing Initiatives
3M ago
Kazia Therapeutics to request FDA Type C meeting
Premium
The Fly
Kazia Therapeutics to request FDA Type C meeting
3M ago
Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development
Premium
Ratings
Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100